COVID-19 in a young liver transplant recipient: caution for drug-drug interactions.

Szczegóły

Tytuł:: COVID-19 in a young liver transplant recipient: caution for drug-drug interactions.
Autorzy:: Dajti E; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. . e_.
Cristini F; Infectious Diseases Unit, Rimini-Forlì-Cesena Hospitals, Rimini, Italy. .
Tamanini G; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. .
Cescon M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. .
Bazzoli F; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. .
Tamè M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. .
Źródło:: Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2020 Sep 09; Vol. 29 (3), pp. 470. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:: Case Reports; Letter
Język:: English
Imprint Name(s):: Original Publication: Cluj-Napoca, Romania : Editura Medicală Universitară "Iuliu Haţieganu", c2006-
MeSH Terms:: Acute Kidney Injury*/chemically induced
Acute Kidney Injury*/diagnosis
Acute Kidney Injury*/prevention & control
Coronavirus Infections*/diagnosis
Coronavirus Infections*/drug therapy
Coronavirus Infections*/physiopathology
Darunavir*/administration & dosage
Darunavir*/adverse effects
Drug Interactions*
Hydroxychloroquine*/administration & dosage
Hydroxychloroquine*/adverse effects
Pandemics*
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/drug therapy
Pneumonia, Viral*/physiopathology
Prednisone*/administration & dosage
Prednisone*/adverse effects
Ritonavir*/administration & dosage
Ritonavir*/adverse effects
Tacrolimus*/administration & dosage
Tacrolimus*/adverse effects
Tacrolimus*/blood
Liver Transplantation/*methods
Adult ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Betacoronavirus/isolation & purification ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/methods ; Drug Monitoring/methods ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/blood ; Male ; Risk Adjustment/methods ; SARS-CoV-2 ; Transplant Recipients ; Treatment Outcome
Substance Nomenclature:: 0 (Antiviral Agents)
0 (Immunosuppressive Agents)
4QWG6N8QKH (Hydroxychloroquine)
O3J8G9O825 (Ritonavir)
VB0R961HZT (Prednisone)
WM0HAQ4WNM (Tacrolimus)
YO603Y8113 (Darunavir)
Entry Date(s):: Date Created: 20200825 Date Completed: 20201001 Latest Revision: 20201218
Update Code:: 20240105
DOI:: 10.15403/jgld-2672
PMID:: 32830825
: Raport

Pełny tekst

Informacja